The acetylcholinesterase inhibitors competitively inhibited an acetyl L-carnitine transport through the blood-brain barrier

Neurochemical Research

Volumn 37, Issue 7, 2012, Pages 1499-1507

  Lee, Na Young ^a   Choi, Hyung Ok ^a   Kang, Young Sook ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Acetyl L carnitine; Acetylcholinesterase inhibitors Brain uptake index; Blood brain barrier; Organic cation carnitine transporter 2; TR BBB cell

Indexed keywords

AMINO ACID TRANSPORTER; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; LEVACECARNINE; ORGANIC CATION TRANSPORTER 2; RIVASTIGMINE; TACRINE;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CAPILLARY ENDOTHELIUM; CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT;

ACETYLCARNITINE; ACETYLCHOLINESTERASE; ANIMALS; BASE SEQUENCE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CELL LINE, TRANSFORMED; CHOLINESTERASE INHIBITORS; DNA PRIMERS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

RATTUS;

EID: 84862846801     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0723-3     Document Type: Article

References (40)

1. Pettegrew JW, Levine J, McClure RJ (2000) Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5:616-632
2. Dolezal V, Tucek S (1981) Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J Neurochem 36:1323-1330
3. Virmani MA, Caso V, Spadoni A et al (2001) The action of acetyl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann NY Acad Sci 939:162-178
4. Mroczkowska JE, Roux FS, Naleçz MJ et al (2000) Blood-brain barrier controls carnitine level in the brain: a study on amodel system with RBE4 cells. Biochem Biophys Res Commun 267:433-437
5. Kido Y, Tamai I, Ohnari A et al (2001) Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 79:959-969
6. Inano A, Sai Y, Nikaido H et al (2003) Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos 24:357-365
7. Friedrich A, Prasad PD, Freyer D et al (2003) Molecular cloning and functional characterization of the OCTN2 transporter at the RBE4 cells, an in vitro model of the blood-brain barrier. Brain Res 968:69-79
8. Berezowski V, Miecz D, Marsza?ek M et al (2004) Involvement of OCTN2 and B0,? in the transport of carnitine through an in vitro model of the blood-brain barrier. J Neurochem 91:860-872
9. Inazu M, Takeda H, Maehara K et al (2006) Functional expression of the organic cation/carnitine transporter 2 in rat astrocytes. J Neurochem 97:424-434
10. Wu X, Huang W, Prasad PD et al (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290:1482-1492
11. Ganapathy ME, Huang W, Rajan DP et al (2000) Beta-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 275:1699-1707
12. Hirano T, Yasuda S, Osaka Y et al (2006) Mechanism of the inhibitory effect of zwitterionic drugs (levofloxacin and grepafloxacin) on carnitine transporter (OCTN2) in Caco-2 cells. Biochim Biophys Acta 1758:1743-1750
13. Hirano T, Yasuda S, Osaka Y et al (2008) The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. Int J Pharm 351:113-118
14. MaNally WP, Pool WF, Sinz MW et al (1996) Distribution of tacrine and metabolites in rat brain and plasma after single-and multiple-dose regimens; evidence for accumulation of tacrine in brain tissue. Drug Metab Dispos 24:628-633
15. Matsui K, Mishima M, Nagai Y et al (1999) Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to rat. Drug Metab Dispos 27:1406-1414
16. Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 20:634-647
17. Kang YS, Lee KE, Lee NY et al (2005) Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB). Arch Pharm Res 28:443-450
18. Lee NY, Kang YS (2010) The inhibitory effect of rivastigmine and galantamine on choline transport in brain capillary endothelial cells. Biomol Ther 18:65-70
19. Thal LJ, Calvani M, Amato A et al (2000) A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology 55: 805-810
20. Bianchetti A, Rozzini R, Trabucchi M (2003) Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 19:350-353
21. Hosoya K, Takashima T, Tetsuka K et al (2000) mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J Drug Target 8:357-370
22. Kang YS, Ohtsuki S, Takanaga Het al (2002) Regulation of taurine transport at the blood-brain barrier by tumor necrosis factor-alpha, taurine and hypertonicity. J Neurochem 83:1188-1195
23. Terasaki T, Hirai K, Sato H et al (1989) Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier. J Pharmacol Exp Ther 251:351-357
24. Terasaki T, Ohtsuki S, Hori S et al (2003) New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov Today 8:944-954
25. Ohashi R, Tamai I, Yabuuchi H et al (1999) Na?-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778-784
26. Ohashi R, Tamai I, Nezu J et al (2001) Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 59:358-366
27. Nakanishi T, Hatanaka T, Huang W et al (2001) Na?-and Clcoupled active transport of carnitine by the amino acid transporter ATB(0, ?) from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol 532:297-304
28. Sloan JL, Mager S (1999) Cloning and functional expression of a human Na? and Cl-dependent neutral and cationic amino acid transporter B0? J Biol Chem 274:740-745
29. Akanuma S, Hori S, Ohtsuki S et al (2008) Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier. Neurochem Int 52: 669-674
30. Gründemann D, Harlfinger S, Golz S et al (2005) Discovery of the ergothioneine transporter. Proc Natl Acad Sci USA 102: 5256-5261
31. Okura T, Hattori A, Takano Y et al (2008) Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36:2005-2013
32. Tachikawa M, Takeda Y, Tomi M et al (2010) Involvement of OCTN2 in the transport of acetyl-L-carnitine across the inner blood-retinal barrier. Invest Ophthalmol Vis Sci 51:430-436
33. Kim MH, Maeng HJ, Yu KH et al (2009) Evidence of carriermediated transport in the penetration of donepezil into the rat brain. J Pharm Sci 99:1548-1566
34. Okura T, Ito R, Ishiguro N et al (2007) Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci 80:1564-1571
35. Bickel U, Thomsen T, Fischer JP et al (1991) Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30:447-454
36. Tiseo PJ, Rogers SL, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 46:13-18
37. Johansson M, Hellstrom-Lindahl E, Nordberg A (1996) Steadystate pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. Dementia 7:111-117
38. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719-739
39. Bajgar J, Bartosova L, Fusek J et al (2007) Changes of cholinesterase activities in the plasma and some tissues following administration of L-carnitine and galanthamine to rats. Neurosci Lett 411:212-216
40. Ramsay RR, Gandour RD, van der Leij FR (2001) Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta 1546:21-43